What is the share price of Wockhardt Ltd (WOCKPHARMA) today?
The share price of WOCKPHARMA as on 1st July 2025 is ₹1677.40. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Wockhardt Ltd (WOCKPHARMA) share?
The past returns of Wockhardt Ltd (WOCKPHARMA) share are- Past 1 week: -3.75%
- Past 1 month: 16.40%
- Past 3 months: 15.85%
- Past 6 months: 15.23%
- Past 1 year: 103.59%
- Past 3 years: 707.02%
- Past 5 years: 549.78%
What are the peers or stocks similar to Wockhardt Ltd (WOCKPHARMA)?
The peers or stocks similar to Wockhardt Ltd (WOCKPHARMA) include:What is the market cap of Wockhardt Ltd (WOCKPHARMA) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Wockhardt Ltd (WOCKPHARMA) is ₹27255.33 Cr as of 1st July 2025.What is the 52 week high and low of Wockhardt Ltd (WOCKPHARMA) share?
The 52-week high of Wockhardt Ltd (WOCKPHARMA) is ₹1868.80 and the 52-week low is ₹730.50.What is the PE and PB ratio of Wockhardt Ltd (WOCKPHARMA) stock?
The P/E (price-to-earnings) ratio of Wockhardt Ltd (WOCKPHARMA) is -579.90. The P/B (price-to-book) ratio is 7.44.Which sector does Wockhardt Ltd (WOCKPHARMA) belong to?
Wockhardt Ltd (WOCKPHARMA) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy Wockhardt Ltd (WOCKPHARMA) shares?
You can directly buy Wockhardt Ltd (WOCKPHARMA) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Wockhardt Ltd
WOCKPHARMA Share Price
WOCKPHARMA Stock Scorecard
Performance
AvgPrice return has been average, nothing exciting
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
AvgAverage profitability - not good, not bad
Entry point
AvgThe stock is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
WOCKPHARMA Performance & Key Metrics
WOCKPHARMA Performance & Key Metrics
No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
---|---|---|
-579.90 | 7.44 | — |
Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
---|---|---|
36.48 | 6.57 | 0.80% |
WOCKPHARMA Analyst Ratings & Forecast
Price Upside
Earnings Growth
Rev. Growth
WOCKPHARMA Company Profile
Wockhardt Limited manufactures and markets pharmaceutical and bio-pharmaceutical formulations, active pharmaceutical ingredients (APIs) and vaccines.
WOCKPHARMA Sentiment Analysis
WOCKPHARMA Sentiment Analysis
WOCKPHARMA Stock Summary · June 2025
Wockhardt Limited is strategically evolving from a generic-focused entity to a global research-driven pharmaceutical leader, showcasing robust financial health with a 67% growth in EBITDA and a minimal net debt to equity ratio. The company is actively expanding its product portfolio, particularly in the diabetes and antibiotic markets, with innovative offerings like Miqnaf and ZAYNICH aimed at addressing critical medical needs and antibiotic resistance. Operational excellence is a priority, as evidenced by cost management initiatives that have maintained profitability despite challenges. With plans to double production capacity and a strong focus on regulatory readiness, Wockhardt is well-positioned to capitalize on emerging market opportunities while fostering investor engagement to support its ambitious growth trajectory.
WOCKPHARMA Stock Growth Drivers
WOCKPHARMA Stock Growth Drivers
8Debt Reduction and Financial Stability
Wockhardt Limited successfully reduced its debt to INR 326 crores, aided by a Qualified Institutional
Advancements in Drug Development
The company has made significant progress in its drug development, particularly with ZAYNICH, which completed
WOCKPHARMA Stock Challenges
WOCKPHARMA Stock Challenges
4Sales Growth Challenges
Wockhardt Limited reported only a 5% growth in sales over the last year, which may
Debt Management Concerns
While the company has successfully reduced its net debt from INR 882 crores in 2022
WOCKPHARMA Forecast
WOCKPHARMA Forecasts
WOCKPHARMA
WOCKPHARMA
Income
Balance Sheet
Cash Flow
WOCKPHARMA Income Statement
WOCKPHARMA Income Statement
Financial Year | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total Revenue | 4,128.86 | 4,057.13 | 3,681.99 | 2,977.36 | 3,825.00 | 3,250.00 | 2,773.00 | 2,881.00 | 3,074.00 | 3,074.00 | ||||||||||
Raw Materials | 1,687.94 | 1,619.00 | 1,605.85 | 1,129.42 | 1,262.00 | 1,180.00 | 1,027.00 | 1,179.00 | 2,619.00 | 2,619.00 | ||||||||||
Power & Fuel Cost | 110.10 | 77.80 | 93.30 | 85.41 | 82.00 | 98.00 | 103.00 | 107.00 | ||||||||||||
Employee Cost | 966.51 | 937.06 | 800.38 | 743.33 | 763.00 | 749.00 | 637.00 | 629.00 | ||||||||||||
Selling & Administrative Expenses | 709.73 | 684.13 | 554.77 | 327.73 | 383.00 | 404.00 | 326.00 | 313.00 | ||||||||||||
Operating & Other expenses | 527.53 | 975.27 | 550.02 | 439.07 | 423.00 | 684.00 | 751.00 | 545.00 | ||||||||||||
EBITDA | 127.05 | -236.13 | 77.67 | 252.40 | 912.00 | 135.00 | -71.00 | 108.00 | 455.00 | 455.00 | ||||||||||
Depreciation/Amortization | 148.93 | 149.53 | 163.95 | 224.14 | 246.00 | 247.00 | 251.00 | 223.00 | 217.00 | 217.00 | ||||||||||
PBIT | -21.88 | -385.66 | -86.28 | 28.26 | 666.00 | -112.00 | -322.00 | -115.00 | 238.00 | 238.00 | ||||||||||
Interest & Other Items | 225.27 | 255.49 | 265.14 | 275.74 | 249.00 | 299.00 | 302.00 | 305.00 | 254.00 | 254.00 | ||||||||||
PBT | -247.15 | -641.15 | -351.42 | -247.48 | 417.00 | -411.00 | -624.00 | -420.00 | -16.00 | -16.00 | ||||||||||
Taxes & Other Items | -51.43 | -32.85 | -156.89 | -178.26 | -269.00 | -167.00 | -65.00 | 43.00 | 31.00 | 31.00 | ||||||||||
Net Income | -195.72 | -608.30 | -194.53 | -69.22 | 686.00 | -244.00 | -559.00 | -463.00 | -47.00 | -47.00 | ||||||||||
EPS | -16.32 | -50.69 | -16.20 | -5.76 | 57.08 | -18.47 | -38.80 | -31.13 | -3.02 | -3.06 | ||||||||||
DPS | 9.22 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||||||
Payout ratio | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
WOCKPHARMA Company Updates
Investor Presentation
WOCKPHARMA Stock Peers
WOCKPHARMA Past Performance & Peer Comparison
WOCKPHARMA Past Performance & Peer Comparison
Health CarePharmaceuticals
Valuation
Technical
Forecast
Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
---|---|---|---|
Wockhardt Ltd | -579.90 | 7.44 | — |
Sun Pharmaceutical Industries Ltd | 36.60 | 5.96 | 0.96% |
Cipla Ltd | 23.22 | 3.91 | 1.06% |
Torrent Pharmaceuticals Ltd | 60.51 | 16.87 | 0.94% |
WOCKPHARMA Stock Price Comparison
Compare WOCKPHARMA with any stock or ETFWOCKPHARMA Holdings
WOCKPHARMA Shareholdings
WOCKPHARMA Promoter Holdings Trend
WOCKPHARMA Promoter Holdings Trend
In last 6 months, promoter holding in the company has decreased by 2.90%
Pledged promoter holdings is insignificant
WOCKPHARMA Institutional Holdings Trend
WOCKPHARMA Institutional Holdings Trend
In last 3 months, retail holding in the company has almost stayed constant
In last 3 months, foreign institutional holding of the company has almost stayed constant
WOCKPHARMA Shareholding Pattern
WOCKPHARMA Shareholding Pattern
WOCKPHARMA Shareholding History
WOCKPHARMA Shareholding History
Mutual Funds Invested in WOCKPHARMA
Mutual Funds Invested in WOCKPHARMA
No mutual funds holding trends are available
Top 5 Mutual Funds holding Wockhardt Ltd
Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
---|---|---|---|---|
The rupee value of the stock held by the fund divided by the stock’s market cap 1.0151% | Percentage of the fund’s portfolio invested in the stock 2.68% | Change in the portfolio weight of the stock over the last 3 months 0.80% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 8/64 (+12) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.6972% | Percentage of the fund’s portfolio invested in the stock 1.21% | Change in the portfolio weight of the stock over the last 3 months 0.29% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 65/109 (+9) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.5150% | Percentage of the fund’s portfolio invested in the stock 1.68% | Change in the portfolio weight of the stock over the last 3 months 0.43% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 23/59 (+9) |
Compare 3-month MF holding change on Screener
smallcases containing WOCKPHARMA stock
smallcases containing WOCKPHARMA stock
Looks like this stock is not in any smallcase yet.
WOCKPHARMA Events
WOCKPHARMA Events
WOCKPHARMA Dividend Trend
WOCKPHARMA has not given any dividends in last 5 years
Dividends
Corp. Actions
Announcements
Legal Orders
WOCKPHARMA Dividend Trend
WOCKPHARMA has not given any dividends in last 5 years
WOCKPHARMA Upcoming Dividends
WOCKPHARMA Upcoming Dividends
No upcoming dividends are available
WOCKPHARMA Past Dividends
WOCKPHARMA Past Dividends
Cash Dividend
Ex DateEx DateNov 17, 2016
Dividend/Share
₹10.00
Ex DateEx Date
Nov 17, 2016
Cash Dividend
Ex DateEx DateNov 13, 2014
Dividend/Share
₹20.00
Ex DateEx Date
Nov 13, 2014
Cash Dividend
Ex DateEx DateFeb 17, 2014
Dividend/Share
₹5.00
Ex DateEx Date
Feb 17, 2014
Cash Dividend
Ex DateEx DateNov 7, 2013
Dividend/Share
₹5.00
Ex DateEx Date
Nov 7, 2013
Cash Dividend
Ex DateEx DateAug 22, 2013
Dividend/Share
₹5.00
Ex DateEx Date
Aug 22, 2013
WOCKPHARMA Stock News & Opinions
WOCKPHARMA Stock News & Opinions
Net Loss of Wockhardt reported to Rs 25.00 crore in the quarter ended March 2025 as against net loss of Rs 169.00 crore during the previous quarter ended March 2024. Sales rose 6.14% to Rs 743.00 crore in the quarter ended March 2025 as against Rs 700.00 crore during the previous quarter ended March 2024. For the full year,net loss reported to Rs 47.00 crore in the year ended March 2025 as against net loss of Rs 463.00 crore during the previous year ended March 2024. Sales rose 7.65% to Rs 3012.00 crore in the year ended March 2025 as against Rs 2798.00 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales743.00700.00 6 3012.002798.00 8 OPM %8.61-8.43 -13.053.25 - PBDT31.00-78.00 LP 201.00-131.00 LP PBT-22.00-136.00 84 -16.00-354.00 95 NP-25.00-169.00 85 -47.00-463.00 90 Powered by Capital Market - Live
Wockhardt will hold a meeting of the Board of Directors of the Company on 29 May 2025.Powered by Capital Market - Live
Wockhardt Bio AG, a subsidiary of Wockhardt, has incorporated a new Wholly Owned Subsidiary in Ireland by the name Wockhardt Antibiotics (Ireland). Consequent to the incorporation, Wockhardt Antibiotics (Ireland) has become a Step-Down Subsidiary of the Company. Powered by Capital Market - Live
The 15-year-old patient, diagnosed with Acute Myeloid Leukemia (AML), had been battling a life-threatening blood and liver infection resistant to nine different antibiotics over 45 days. The infection, caused by NDM-producing E. coli, persisted despite treatment with multiple last-resort antibiotics, including Tigecycline, Polymyxin B, and Ceftazidime/avibactam + Aztreonam. With limited treatment options left, doctors at St. Jude's Hospital, Memphis, USA, sought compassionate use approval from the US FDA to administer Zaynich. Over 41 days of treatment, the patient made a full recovery, marking the third successful US case treated with Wockhardt's novel β-lactam enhancer antibiotic. Zaynich, a proprietary β-lactam enhancer antibiotic, has now been used under compassionate use in 51 critically ill patients globally, demonstrating its potential against multi-drug resistant Gram-negative infections. The drug recently completed Phase III global trials, paving the way for marketing approvals worldwide. Wockhardt is a research based global pharmaceutical and biotech company. The company reported consolidated net profit of Rs 14 crore in Q3 FY25 as against net loss of Rs 83 crore in Q3 FY24. Net sales rose 2.9% year on year to Rs 721 crore in Q3 FY25. Powered by Capital Market - Live
Wockhardt will hold a meeting of the Board of Directors of the Company on 7 February 2025.Powered by Capital Market - Live
Miqnaf is an ultra-short course, once-a-day, 3-day treatment for CABP, including those caused by multi-drug-resistant (MDR) pathogens. The approval follows a favourable recommendation for manufacture and marketing of nafithromycin from the Subject Expert Committee (SEC) of CDSCO. Over 15 years, Miqnaf underwent extensive non-clinical and clinical studies, including human trials in the US, Europe, South Africa, and India. It represents a new macrolide-based treatment for CABP in India after a gap of nearly 30 years. Moreover, the ultra-short course regimen is said to enhance patients' compliance with treatment, resulting in favourable outcomes. In India, antibiotic resistance is a burning issue, including in community pneumonia cases. A key strength of Miqnaf is its ability to target a wide range of respiratory infections, including bacteria resistant to common antibiotics like azithromycin and amoxicillin/clavulanate, making it a strong single-treatment option for pneumonia. CABP affects millions of people worldwide, with 23% of the global disease burden borne by India. Several bacterial pathogens could cause CABP and other respiratory infections, the dominant being S. pneumoniae and H. influenzae and atypical respiratory pathogens such as Mycoplasma, Chlamydia, and Legionella. Mumbai-based Wockhardt is a research-based global pharmaceutical and biotech company. Employing around ~2600 people and 27 nationalities, it has a presence in the USA, UK, Ireland, Switzerland, France, Mexico, Russia, and many other countries. It has manufacturing and research facilities in India and the UK and a manufacturing facility in Ireland. Around 78% of its global revenues are coming from international businesses. The company reported consolidated net loss of Rs 16 crore in Q2 FY25 as against net loss of Rs 35 crore posted in Q2 FY24. Net sales rose 7.43% year on year to Rs 809 crore in Q2 FY25.Powered by Capital Market - Live
Net Loss of Wockhardt reported to Rs 22.00 crore in the quarter ended September 2024 as against net loss of Rs 77.00 crore during the previous quarter ended September 2023. Sales rose 7.44% to Rs 809.00 crore in the quarter ended September 2024 as against Rs 753.00 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales809.00753.00 7 OPM %13.609.56 - PBDT46.0020.00 130 PBT-9.00-35.00 74 NP-22.00-77.00 71 Powered by Capital Market - Live
Wockhardt will hold a meeting of the Board of Directors of the Company on 13 November 2024Powered by Capital Market - Live
The floor price indicates a steep discount of 8.5% over the stock's closing price on Wednesday. The media reported that the QIP is aimed to raise up to Rs 1,000 crore, with an additional greenshoe option of Rs 200 crore. A QIP is a method by which a company raises funds by allotting shares to eligible institutional buyers. According to reports, the QIP is expected to dilute Wockhardt's equity by around 5.57% of its post-issue capital. Based on the September shareholding pattern, promoters of Wockhardt held a 51.99% stake in the company. Mumbai-based Wockhardt is a research based global pharmaceutical and biotech company. Employing around ~2600 people and 27 nationalities, it has a presence in USA, UK, Ireland, Switzerland, France, Mexico, Russia and many other countries. It has manufacturing and research facilities in India & UK and a manufacturing facility in Ireland. Around 78% of its global revenues is coming from international businesses. Powered by Capital Market - Live
Wockhardt announced the filing of its fast-acting insulin analog, Aspart injection (ASPARAPID), with the Drugs Controller General of India (DCGI). This significant milestone reflects Wockhardt's ongoing commitment to address the growing diabetes epidemic both in India and globally. Wockhardt's Aspart insulin injection (ASPARAPID) is an indigenously developed product, underscoring the company's end-to-end capabilities in research development - from research to production through in-house development. It offers enhanced quality and accessibility for patients. ASPARAPID will be available in cartridges, vials, and prefilled disposable pens, offering flexibility to the patients for management of diabetes. The market size of Aspart in India is currently estimated over Rs 260 crore with only 2 players and is expected to grow significantly in the coming years. 'We are proud of adding another feather in our diabetes biosimilars portfolio through filing of insulin Aspart injection in a market that has limited competition. This reinforces Wockhardt's ability to develop and manufacture complex biosimilars domestically,' said Dr. Habil Khorakiwala, Founder Chairman of Wockhardt. 'Our aim is to make world-class diabetes care accessible to patients in India and globally and to contribute meaningfully to the management of diabetes.' Wockhardt is also developing additional insulin analogs and GLP-1 agonists as part of its comprehensive strategy to provide advanced diabetes care solutions. The introduction of these products will further strengthen Wockhardt's diabetes portfolio, offering patients more effective treatment options for managing their condition. Powered by Capital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of 0.64%, vs industry avg of 10.2%
Over the last 5 years, market share decreased from 1.19% to 0.74%